Dengue virus type 1 envelope protein antigen and Dengue virus type 3 envelope protein antigen (DEN-1 ED3 antigen and DEN-3 ED3 antigen)

The dengue virus type 1 and type 3 envelope protein antigens, specifically the domain III region (ED3), are major surface proteins critical for viral entry and targeted by neutralizing antibodies. These antigens present conformational epitopes recognized by type-specific, subcomplex-specific, and cross-reactive antibodies, and play a central role in vaccine development and serological diagnostics. They are not human proteins but rather viral proteins that serve as direct antigenic targets for the host immune response and for therapeutic intervention. Note: The naming "Dengue virus type 1 and type 3 antigens" should be replaced with the precise molecular target: for example, "Dengue virus type 1 envelope protein domain III antigen" (DEN-1 ED3 antigen). These envelope protein antigens are widely used as both immunogens in research and as diagnostic reagents in serology. They are essential for viral infectivity and immunogenicity, forming the main basis for current therapeutic monoclonal antibody and vaccine strategies.

Other names

Dengue virus serotype 1 envelope antigenDengue virus serotype 3 envelope antigenDEN-1 E antigenDEN-3 E antigenDEN-1 protein EDEN-3 protein EDENV1 ED3DENV3 ED3

Neutralization — Antibodies bind the envelope protein domain III, blocking viral attachment, fusion, or entry into host cells. Inhibition of membrane fusion — Some antibodies sterically hinder critical fusion steps. Antibody binding may prevent the formation of functional viral trimers.